Different kinetic patterns of BCR‐ABL transcript levels in imatinib‐treated chronic myeloid leukemia patients after achieving complete cytogenetic response
YZ Qin, YR Liu, HH Zhu, JL Li, GR Ruan… - International Journal …, 2008 - Wiley Online Library
Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
J Moravcová, V Zmeková, H Klamová, J Voglová… - Leukemia research, 2004 - Elsevier
Kinetics of BCR-ABL transcript levels were determined in 19 patients with chronic myeloid
leukemia (CML) treated with imatinib for chronic (CP) or accelerated phase (AP). Patients …
leukemia (CML) treated with imatinib for chronic (CP) or accelerated phase (AP). Patients …
Monitoring of BCR-ABL Transcirpt Levels after Discontinuation of Imatinib Therapy in Chronic Myelogenous Leukemia Patients Achieving Complete Cytogenetic …
YJ Kim, DW Kim, S Lee, KS Eom, CK Min, HJ Kim… - 2004 - ashpublications.org
Background Imatinib induces a high complete cytogenetic response (CCR) rate in chronic
myelogenous leukemia (CML). None of the studies addressed the important question of how …
myelogenous leukemia (CML). None of the studies addressed the important question of how …
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL
Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
MC Müller, N Gattermann, T Lahaye, MWN Deininger… - Leukemia, 2003 - nature.com
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
M Hardling, Y Wei, L Palmqvist, B Swolin… - Medical oncology, 2004 - Springer
Survival among chronic myelogenous leukemia (CML) patients can be linked to the
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka… - Leukemia, 2002 - nature.com
The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid …
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
相关搜索
- leukemia patients bcr abl
- imatinib mesylate bcr abl
- transcript levels bcr abl
- transcript levels cml patients
- transcript levels cytogenetic response
- cml patients cytogenetic response
- abl mrna cytogenetic response
- transcript levels imatinib mesylate
- chronic phase bcr abl
- cml patients chronic phase
- prediction of response bcr abl
- leukemia patients imatinib therapy
- leukemia patients prediction of response
- cml patients abl mrna
- imatinib mesylate patients with cml
- transcript levels disease phase